Matthew Campbell et al. have recently published a new study in the journal of Geroscience demonstrating Elamipretide effects on the skeletal muscle phosphoproteome in aged female mice. Elamipretide (ELAM) is a short tetrapeptide that interacts with cardiolipin and cardiolipin-interacting proteins on the inner mitochondrial membrane. It improves in vivo mitochondria function, increase fatigue resistance, and restore redox status in skeletal muscle of aged female mice.

This study was designed to investigate whether ELAM could alter protein expression or post-translational modifications in skeletal muscle. To accomplish this, aged female mice were treated with ELAM for 8 weeks to measure changes in protein abundance and the phosphoproteome compared to untreated age matched controls and untreated young animals.